DIAGNOSTIC ROLE OF GALECTIN-3 EXPRESSION IN BENIGN FOLLICULAR PATTERNED THYROID LESIONS, NON-INVASIVE FOLLICULAR THYROID NEOPLASM WITH PAPILLARY-LIKE NUCLEAR FEATURES (NIFTP), AND INFILTRATIVE FOLLICULAR VARIANT PAPILLARY THYROID CARCINOMA (IFVPTC)
DOI:
https://doi.org/10.22159/ajpcr.2023.v16i6.47696Keywords:
Galectin-3, immunohistochemistry, Non-invasive Follicular Thyroid neoplasm with papillary-like nuclear features, Follicular variant Papillary Thyroid CarcinomaAbstract
Objectives: The objective of the study was to determine the role of Galectin-3 expression in distinguishing Benign follicular patterned thyroid lesions, non- Invasive follicular thyroid neoplasm with papillary-like nuclear Features (NIFTP), and invasive follicular variant of papillary thyroid carcinoma (IFVPTC).
Methods: The Institutional Human Ethics Committee reference number is 271/pathology/09/2022. A total of 85 cases were included in the study after the histopathological evaluations based on strictly defined inclusion and exclusion criteria. Study groups were created as nodular hyperplasia, follicular adenoma, follicular carcinoma, NIFTP, invasive EFVPTCs, and classical papillary thyroid carcinomas. Cytoplasmic Galectin-3 Immunohistochemistry (IHC) expression was evaluated in these cases. Galectin-3 IHC scores data were analyzed using IBM SPSS statistics. The Chi-square test was used to determine the association between the variables. p<0.05 was considered statistically significant.
Results: Cytoplasmic galectin-3 IHC expression was significantly increased in malignant follicular patterned thyroid lesions compared to benign lesions with p<0.00001. Similarly, cytoplasmic galectin-3 IHC expression was significantly increased in IFVPTC when compared to NIFTP with a p-value of 0.01358. The Odds Ratio showed the positive cytoplasmic Galectin-3 expression in IFVPTC with a 7.5 times higher risk of having adverse outcome when compared to NIFTP.
Conclusion: Cytoplasmic Galectin-3 IHC expression may serve as a useful biomarker in predicting the invasiveness of FVPTC and distinguishing NIFTP from infiltrative FVPTC.
Downloads
References
Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: A paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol 2016;2:1023-9. doi: 10.1001/jamaoncol.2016.0386, PMID: 27078145; PMCID: PMC5539411
Seethala RR, Baloch ZW, Barletta JA, Khanafshar E, Mete O, Sadow PM, et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: A review for pathologists. Mod Pathol 2018;31:39-55. doi: 10.1038/modpathol.2017.130. PMID: 29052599
Bychkov A, Jung CK, Liu Z, Kakudo K. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features in Asian practice: Perspectives for surgical pathology and cytopathology. Endocr Pathol 2018;29:276-88. doi: 10.1007/s12022-018-9519-6. PMID: 29476382; PMCID: PMC6097061
Zajkowska K, Kopczyński J, Góźdź S, Kowalska A. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: A problematic entity. Endocr Connect 2020;9:R47-58. doi: 10.1530/ EC-19-0566. PMID: 32061158; PMCID: PMC7077601
Pusztaszeri M, Bongiovanni M. The impact of non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) on the diagnosis of thyroid nodules. Gland Surg 2019;8 Suppl 2:S86-97. doi: 10.21037/gs.2018.12.01. PMID: 31475095; PMCID: PMC6694025
Hodak S, Tuttle RM, Maytal G, Nikiforov YE, Randolph G. Changing the cancer diagnosis: The case of follicular variant of papillary thyroid cancer-primum non nocere and NIFTP. Thyroid 2016;26:869-71. doi: 10.1089/thy.2016.0205. PMID: 27184034
Rosario PW, Mourão GF. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): A review for clinicians. Endocr Relat Cancer 2019;26:R259-66. doi: 10.1530/ERC-19-0048. PMID: 30913533
Alves VA, Kakudo K, LiVolsi V, Lloyd RV, Nikiforov YE, Nosé V, et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): Achieving better agreement by refining diagnostic criteria. Clinics (Sao Paulo) 2018;73:e576. doi: 10.6061/clinics/2018/ e576. PMID: 29791602; PMCID: PMC5952051
Cho U, Mete O, Kim MH, Bae JS, Jung CK. Molecular correlates and rate of lymph node metastasis of non-invasive follicular thyroid neoplasm with papillary-like nuclear features and invasive follicular variant papillary thyroid carcinoma: The impact of rigid criteria to distinguish non-invasive follicular thyroid neoplasm with papillary-like nuclear features. Mod Pathol 2017;30:810-25. doi: 10.1038/ modpathol.2017.9. PMID: 28281551
Fu G, Polyakova O, Chazen RS, Freeman JL, Witterick IJ. Diagnostic value of galectin-3 in distinguishing invasive encapsulated carcinoma from noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP). Cancers (Basel) 2021;13:2988. doi: 10.3390/ cancers13122988. PMID: 34203725; PMCID: PMC8232163
Tang W, Huang C, Tang C, Xu J, Wang H. Galectin-3 may serve as a potential marker for diagnosis and prognosis in papillary thyroid carcinoma: A meta-analysis. Onco Targets Ther 2016;9:455-60. doi: 10.2147/OTT.S94514. PMID: 26858526; PMCID: PMC4730995
Saggiorato E, Cappia S, De Giuli P, Mussa A, Pancani G, Caraci P, et al. Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab 2001;86:5152-8. doi: 10.1210/jcem.86.11.8043. PMID: 11701669
Trimboli P, Virili C, Romanelli F, Crescenzi A, Giovanella L. Galectin-3 performance in histologic a cytologic assessment of thyroid nodules: A systematic review and meta-analysis. Int J Mol Sci 2017;18:1756. doi: 10.3390/ijms18081756. PMID: 28800068; PMCID: PMC5578146
Tastekin E, Keskin E, Can N, Canberk S, Mut A, Erdogan E, et al. CD56, CD57, HBME1, CK19, Galectin-3 and p63 immunohistochemical stains in differentiating diagnosis of thyroid benign/malign lesions and NIFTP. Pol J Pathol 2019;70:286-94. doi: 10.5114/pjp.2019.93131. PMID: 32146798
Fu G, Polyakova O, MacMillan C, Ralhan R, Walfish PG. Programmed death - ligand 1 expression distinguishes invasive encapsulated follicular variant of papillary thyroid carcinoma from noninvasive follicular thyroid neoplasm with papillary-like nuclear features. EBioMedicine 2017;18:50-5. doi: 10.1016/j.ebiom.2017.03.031. PMID: 28363612; PMCID: PMC5405181
Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F,Rossetto R, et al. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: A prospective multicentre study. Lancet Oncol 2008;9:543-9. doi: 10.1016/S1470-2045(08)70132-3. PMID: 18495537
Huang L, Wang X, Huang X, Gui H, Li Y, Chen Q, et al. Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma. Oncol Lett 2018;15:4269-77. doi: 10.3892/ol.2018.7873. PMID: 29541194; PMCID: PMC5835856
Zhu X, Sun T, Lu H, Zhou X, Lu Y, Cai X, et al. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma. J Clin Pathol 2010;63:786-9. doi: 10.1136/jcp.2010.076901. PMID: 20644217
Chuang HW, Wang JS, Tsai JW, Hsu CT, Lin KJ. Immunohistochemistry helps to distinguish noninvasive follicular thyroid neoplasm with papillary-like nuclear features/noninvasive encapsulated follicular variant of papillary thyroid carcinoma with other follicular thyroid lesions. Medicina (Kaunas) 2021;57:1246. doi: 10.3390/ medicina57111246. PMID: 34833464; PMCID: PMC8624760
Cho H, Kim JY, Oh YL. Diagnostic value of HBME-1, CK19, galectin 3, and CD56 in the subtypes of follicular variant of papillary thyroid carcinoma. Pathol Int 2018;68:605-13. doi: 10.1111/pin.12729. PMID: 30350394
Published
How to Cite
Issue
Section
Copyright (c) 2023 Tamilselvi Veeramani, Lakshmy , Ravikumar Krishnan , Divya Rajendran
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
